Enerisant HCl

CAS No. 1152749-07-9

Enerisant HCl( —— )

Catalog No. M36346 CAS No. 1152749-07-9

Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 141 Get Quote
5MG 216 Get Quote
10MG 347 Get Quote
25MG 545 Get Quote
50MG 788 Get Quote
100MG 1035 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Enerisant HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
  • Description
    Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    P450
  • Recptor
    P450 | Histamine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1152749-07-9
  • Formula Weight
    434.96
  • Molecular Formula
    C22H31ClN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=O)(C1=CN(N=C1)C2=CC=C(OCCCN3[C@H](C)CCC3)C=C2)N4CCOCC4.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • CYP1B1-IN-4

    CYP1B1-IN-4, a 2,4-diarylthiazole compound, exhibits selective inhibition of CYP1B1 (IC50=0.2 nM), demonstrating minimal cytotoxicity and high stability in human and rat liver microsomes .

  • Proadifen hydrochlor...

    Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM).

  • CYP1B1-IN-7

    CYP1B1-IN-7 is a selective and potent CYP1B1 inhibitor showing cytotoxic effects in docetaxel-resistant CYP1B1 overexpressing MCF-7 cell lines, and can be used in synergistic treatment of cancer with anticancer compounds.